The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma (Review)

International Journal of Oncology

Volumn 12, Issue 3, 1998, Pages 569-576

  Stack, M Sharon ^a   Ellerbroek, Shawn M ^a   Fishman, David A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Extracellular matrix; Gelatinase; Matrix metalloproteinase; Ovarian carcinoma; Plasminogen activator; Proteinases; Urokinase

Indexed keywords

MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR; PROTEINASE;

CANCER INVASION; EPITHELIUM CELL; HUMAN; OVARY CARCINOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; REVIEW;

EID: 0031883203     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Godwin AK, Testa JR and Hamilton TC: The biology of ovarian cancer development. Cancer 71: 530-536, 1993.
2. Auersperg N, Maines-Bandiera SL and Kruk PA: Human ovarian surface epithelium: growth patterns and differentiation. In: Ovarian Cancer III. Sharp F, Mason P, Blacket T and Berek J (eds.) Chapman Hall, London, pp 157-169, 1994.
3. Czernobilsky B, Moll R, Levy M and Franke WW: Coexpression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary. Eur J Cell Biol 37: 175-190, 1985.
4. Auersperg N, Maclaren IA and Kruk PA: Ovarian surface epithelium: autonomous production of connective tissue-type extracellular matrix. Biol Reprod 44: 717-724, 1991.
5. Scully RE: Common epithelial tumors. In: Atlas of Tumor Pathology: Tumors of the Ovary and Maldeveloped Gonads. Hartman WH (ed.) Armed Forces Institute of Pathology, Washington, DC, pp53-151, 1979.
6. Hoskins WJ: Prospective on ovarian cancer: Why prevent? J Cell Biochem Suppl 23: 189-199, 1995.
7. Liotta LA, Rao NC and Wewer UM: Biochemical interactions of tumor cells with the basement membrane. Ann Rev Biochem 55: 1037-1057, 1986.
8. Mignatti P and Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195, 1993.
9. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-166, 1985.
10. Robbins KC, Summaria L, Hsieh B and Shah RJ: The peptide chains of human plasmin. Mechamism of activation of human plasminogen to plasmin. J Biol Chem 242: 2333-2342, 1967.
11. Woessner JF: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145-2154, 1991.
12. Van Wart HE and Birkedal-Hansen H: The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87: 5578-5582, 1990.
13. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E and Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65, 1994.
14. Puente XS, Pendas AM, Llano E, Velasco G and Lopez-Otin C: Molecular cloning of a novel membrane-type metalloproteinase from a human breast carcinoma. Cancer Res 56: 944-949, 1996.
15. Takino T, Stao H, Shinagawa A and Seiki M: Identification of the second membrane-type matrix metalloproteinase gene from a human placenta cDNA library. J Biol Chem 270: 23013-23020, 1995.
16. Will H and Hinzmann B: cDNA sequence and mRNA distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 231: 602-608, 1995.
17. Travis J and Salvesen GS: Human plasma proteinase inhibitors. Ann Rev Biochem 52: 655-709, 1983.
18. Sottrup-Jensen L: Alpha macroglobulins: structure, shape and mechanism of proteinase complex formation. J Biol Chem 264: 11539-11542, 1989.
19. Wilhelm O, Hafter R, Coppenrath E, Pflanz MA, Schmitt, Babic R, Linke R, Gossner W and Graeff H: Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. Cancer Res 48: 3507-3514, 1988.
20. Hafter R, Klaubert W, Gollwitzer R, von Hugo R and Graeff H: Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis. Thromb Res 35: 53-64, 1984.
21. Crickard K, Niedbala MJ, Crickard U, Yoonessi M, Sandberg AA, Okuyama K, Bernacki RJ and Satchidanand SK: Characterization of human ovarian and endometrial carcinoma cell lines established on extracellular matrix. Gynecol Oncol 32: 163-173, 1989.
22. Niedbala MJ, Crickard K and Bernacki RJ: In vitro degradation of extracellular matrix by human ovarian carcinoma cells. Clin Exp Metastasis 5: 181-197, 1987.
23. Astedt B, Svanberg L and Nilsson IM: Fibrin degradation products and ovarian tumors. Br Med J 4: 458-459, 1971.
24. Karlan BY, Amin W, Band V, Zurawski VR and Littlefield BA: Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. Gynecol Oncol 31: 103-112, 1988.
25. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC and Stack MS: Secretion of extracellular matrix degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 56: 552-559, 1994.
26. Casslen B, Gustavsson B and Astedt B: Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumors. Eur J Cancer 27: 1445-1448, 1991.
27. Young TN, Rodriguez GC, Moser TL, Bast RC, Pizzo SV and Stack MS: Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 170: 1285-1296, 1994.
28. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T and Terao T: Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 52: 3610-3614, 1992.
29. Wilhelm O, Weidle U, Hohl S, Rettenberger P, Schmitt M and Graeff H: Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). FEBS Lett 337: 131-134, 1994.
30. Wilhelm O, Schmitt M, Hohl S, Senekowitsch R and Graeff H: Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 13: 296-302, 1995.
31. Pujade-Lauraine H, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof EKO, Lijnen HR and Burtin P: The plasminogen activation system in ovarian tumors. Int J Cancer 55: 27-31, 1993.
32. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Janicke F and Graeff H: Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55: 401-409, 1994.
33. Van der Burg ME, Henzen-Logmans SC, Berns EM, van Putten WL and Klijn JG, Foekens JA: Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer 69: 475-479, 1996.
34. Casslen B, Bossmar T, Lecander I and Astedt B: Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 30A: 1302-1309, 1994.
35. Estreicher A, Mulhauser J, Carpentier JL, Orci L and Vassalli JD: The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. Cell Biol 111: 783-792, 1990.
36. Cubellis MV, Wun TC and Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079-1085, 1990.
37. Andreasen PA, Kjoller L, Christensen L and Duffy M: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
38. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F and Dano K: Cellular receptor for urokinase plasminogen activator: carboxy terminal processing and membrane anchoring by glycosylphosphatidylinositol. J Biol Chem 266: 1926-1933, 1991.
39. Pedersen N, Schmitt M, Ronne E, Nicoletti MI, Hoyer-Hansen G, Conese M, Giavazzi R, Dano K, Kuhn W, Janicke F and Blasi F: A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 92: 2160-2167, 1993.
40. Chambers SK, Gertz RE, Ivins CM and Kacinski BM: The significance of urokinase-type plasminogen activator, its inhibitors and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 75: 1627-1633, 1995.
41. Larsh S, Kearns A, Enghild J, Fishman D, Bafetti L and Stack S: Autocrine regulation of growth stimulation in epithelial ovarian carcinoma by urinary type plasminogen activator. Fibrinolysis 10 (Suppl): 115, 1996.
42. Fischer K, Lutz V, Schmitt M, Graeff H, Luther T, Wilhelm O, Magdolen V and Reuning U: The urokinase-type plasminogen activator promotes proliferation of human ovarian carcinoma cells. Fibrinolysis Proteolysis 11 (Suppl): 12, 1997.
43. Young TN, Rodriguez GC, Rinehart AR, Bast RC, Pizzo SV and Stack MS: Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 62: 89-99, 1996.
44. Fishman, DA, Bafetti LM, Banionis S, Kearns AS, Chilukuri K, and Stack MS: Production of extracellular matrix degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 80: 1457-1463, 1997.
45. Fishman DA, Bafetti LM and Stack MS: Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 16: 150-159, 1996.
46. Young TN, Pizzo SV and Stack MS: A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2. J Biol Chem 270: 999-1002, 1995.
47. Takemura M, Azuma C, Kimura T, Kanai T, Saji F and Tanizawa O: Type IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissues. Int J Gynecol Obstet 46: 303-309, 1994.
48. Liebman JM, Burbelo PD, Yamada Y, Fridman R and Kleinman HK: Altered expression of basement membrane components and collagenases in ascitic xenografts of OVCAR-3 ovarian cancer cells. Int J Cancer 55: 102-109, 1993.
49. Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG and Liotta LA: Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 16: 500-507, 1992.
50. De Nictolis M, Garbisa S, Lucarini G, Goteri G, Masiero L, Ciavattini A, Garzetti GG, Stetler-Stevenson WG, Fabris G, Biagini G and Prat J: 72 kilodalton type IV collagenase, type IV collagen and Ki-67 antigen in serous tumors of the ovary: a clinicopathologic, immunohistochemical and serological study. Int J Gyn Pathol 15: 102-109, 1996.
51. Afzal S, Lalani EN, Foulkes WD, Boyce B, Tickle S, Cardillo MR, Baker T, Pignatelli M and Stamp GWH: Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 74: 406-421, 1996.
52. Naylor MS, Stamp GW, Davies BD and Balkwill FR: Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer 58: 50-56, 1994.
53. Autio-Harmainen H, Karttunen T, Hurskainen T, Hoyhtya M, Kauppila A and Tryggvason K: Expression of 72 kDa type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest 69: 312-321, 1993.
54. Davies B, Brown PD, East N, Crimmin MJ and Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087-2091, 1993.
55. Brown PD: Matrix metalloproteinase inhibitors: a novel class of anti-cancer agents. Adv Enzyme Regul 35: 293-301, 1995.
56. Brown PD: Clinical trials of a low molecular weight matrix metalloproteinase inhibitor in cancer. Ann NY Acad Sci 732: 217-221, 1994.
57. Garzetti GG, Ciavatini A, Lucarini G, Goteri G, de Nictolis M, Garbisa S, Masiero L, Romanini C and Graziella B: Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res 15: 2799-2804, 1995.
58. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, Romanini C and Biagini G: Increased serum 72 kDa metalloproteinase in serous ovarian tumors: comparison with CA125. Anticancer Res 16: 2123-2128, 1996.
59. Hirahara F, Miyagi Y, Miyagi E, Yasumitsu H, Koshikawa N, Nagashima Y, Kitamura H, Minaguchi H, Umeda M and Miyazaki K: Trypsinogen expression in human ovarian carcinomas. Int J Cancer 63: 176-181, 1995.
60. Kobayashi H, Fujie M, Shinohara H, Ohi H, Sugimura M and Terao T: Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells. Int J Cancer 57: 378-384, 1994.
61. Medl M, Ogris E, Peters-Engl C and Leodolter S: TATI (tumor-associated trypsin inhibitor) as a marker of ovarian cancer. Br J Cancer 71: 1051-1054, 1995.
62. Tanimoto H, Yan Y, Clarke J, Korourian S, Shigemasa K, Parmley TH, Parham GP and O'Brien TJ: Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 57: 2884-2887, 1997.
63. Karlan BY, Rivero JA, Crabtree ME and Littlefield BA: Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells. Mol Endocrinol 3: 1006-1013, 1989.
64. Chambers SK, Wang Y, Gertz RE and Kacinski BM: Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 55: 1578-1585, 1995.
65. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P, Love S, Scott WN, Williams AR, Lessells AM, Macleod KG, Smyth JF and Miller WR: The prognostic value of epidermal growth factor mRNA expression in primary ovarian cancer. Br J Cancer 73: 301-306, 1996.
66. Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W and Schauer A: Overexpression of the oncogene c-erbB2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 13: 45-53, 1994.
67. Ellerbrock SM, Hudson LG, Fishman DA, Bafetti LM, Kearns AS, Chiklukuri K and Stack MS: Epidermal growth factor induces u-PA and MMP-9 production and regulates the invasive behavior of epithelial ovarian carcinoma cells. Fibrinolysis Proteolysis 11 (Suppl): 13, 1997.
68. Westerlund A, Hujanen E, Puistola U and Turpeenniemi-Hujanen T: Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72 kDa gelatinase A (MMP-2). Gyn Oncol 67: 76-82, 1997.
69. Moser TL, Pizzo SV, Bafetti LM, Fishman DA and Stack MS: Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the α2βI integrin. Int J Cancer 67: 695-701, 1996.